• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miR-4262 通过负向调控 KLF6 水平抑制食管癌的发展。

MiR-4262 inhibits the development of esophageal cancer by negatively regulating KLF6 level.

机构信息

Department of Thoracic Surgery, Caoxian People's Hospital, Heze, China.

Department of Respiratory Medicine, Caoxian People's Hospital, Heze, China.

出版信息

Exp Mol Pathol. 2020 Aug;115:104476. doi: 10.1016/j.yexmp.2020.104476. Epub 2020 May 28.

DOI:10.1016/j.yexmp.2020.104476
PMID:32473153
Abstract

OBJECTIVE

To uncover the expression pattern and the prognosis of miR-4262 in these patients with esophageal cancer, and its potential mechanism.

METHODS

MiR-4262 levels in 57 esophageal cancer and paracancerous specimens were detected. The relationship between miR-4262 level and clinical features of esophageal cancer was analyzed. After overexpression of miR-4262 in OE19 and EC-109 cells, changes in proliferative potential and apoptosis were examined. The interaction between miR-4262 and KLF6 was explored by dual-luciferase reporter assay. Their involvement in the development of esophageal cancer was finally determined.

RESULTS

MiR-4262 was downregulated in esophageal cancer specimens and cell lines. Low level of miR-4262 predicted advanced pathological staging and poor prognosis in esophageal cancer patients. Overexpression of miR-4262 reduced proliferative potential and enhanced apoptosis in esophageal cancer cells. KLF6 was the downstream gene binding to miR-4262. The interaction between miR-4262 and KLF6 was responsible for alleviating the malignant development of esophageal cancer.

CONCLUSIONS

MiR-4262 is downregulated in esophageal cancer and linked to its pathological staging and prognosis. MiR-4262 inhibits the malignant development of esophageal cancer by down-regulating KLF6.

摘要

目的

揭示 miR-4262 在这些食管癌患者中的表达模式和预后及其潜在机制。

方法

检测 57 例食管癌及癌旁标本中 miR-4262 水平。分析 miR-4262 水平与食管癌临床特征的关系。在 OE19 和 EC-109 细胞中转染过表达 miR-4262,检测增殖能力和凋亡的变化。通过双荧光素酶报告基因实验探索 miR-4262 与 KLF6 的相互作用。最后确定它们在食管癌发展中的作用。

结果

miR-4262 在食管癌标本和细胞系中下调。miR-4262 低表达预示食管癌患者的病理分期较晚,预后不良。过表达 miR-4262 可降低食管癌细胞的增殖能力,促进凋亡。KLF6 是与 miR-4262 结合的下游基因。miR-4262 与 KLF6 的相互作用负责减轻食管癌的恶性发展。

结论

miR-4262 在食管癌中下调,与食管癌的病理分期和预后相关。miR-4262 通过下调 KLF6 抑制食管癌的恶性发展。

相似文献

1
MiR-4262 inhibits the development of esophageal cancer by negatively regulating KLF6 level.miR-4262 通过负向调控 KLF6 水平抑制食管癌的发展。
Exp Mol Pathol. 2020 Aug;115:104476. doi: 10.1016/j.yexmp.2020.104476. Epub 2020 May 28.
2
Up-regulation of miR-181a in clear cell renal cell carcinoma is associated with lower KLF6 expression, enhanced cell proliferation, accelerated cell cycle transition, and diminished apoptosis.透明细胞肾细胞癌中miR-181a的上调与KLF6表达降低、细胞增殖增强、细胞周期过渡加速及细胞凋亡减少有关。
Urol Oncol. 2018 Mar;36(3):93.e23-93.e37. doi: 10.1016/j.urolonc.2017.09.019. Epub 2017 Oct 21.
3
MiR-200c-3p aggravates gastric cell carcinoma via KLF6.miR-200c-3p 通过 KLF6 加重胃癌细胞。
Genes Genomics. 2021 Nov;43(11):1307-1316. doi: 10.1007/s13258-021-01160-6. Epub 2021 Sep 15.
4
LncRNA CASC11 promotes the development of esophageal carcinoma by regulating KLF6.长链非编码 RNA CASC11 通过调节 KLF6 促进食管癌的发展。
Eur Rev Med Pharmacol Sci. 2019 Oct;23(20):8878-8887. doi: 10.26355/eurrev_201910_19283.
5
MiRNA-21-5p Accelerates EMT and Inhibits Apoptosis of Laryngeal Carcinoma via Inhibiting KLF6 Expression.微小RNA-21-5p通过抑制KLF6表达促进喉癌上皮-间质转化并抑制其凋亡
Biochem Genet. 2023 Feb;61(1):101-115. doi: 10.1007/s10528-022-10246-z. Epub 2022 Jun 27.
6
MiR-191-5p inhibits KLF6 to promote epithelial-mesenchymal transition in breast cancer.miR-191-5p 通过抑制 KLF6 促进乳腺癌上皮间质转化。
Technol Health Care. 2023;31(6):2251-2265. doi: 10.3233/THC-230217.
7
The Super Enhancer Modulates Cell Proliferation MiR-1301 in Human Hepatoma Cells.超级增强子调节人肝癌细胞中miR-1301的细胞增殖
Microrna. 2020;9(1):64-69. doi: 10.2174/2211536608666190314122725.
8
Expression of KLF6-SV2 in colorectal cancer and its impact on proliferation and apoptosis.KLF6-SV2在结直肠癌中的表达及其对增殖和凋亡的影响。
Eur J Cancer Prev. 2018 Jan;27(1):20-26. doi: 10.1097/CEJ.0000000000000410.
9
Krüppel-Like Factor 6 Downregulation Is Connected with a Poor Prognosis and Tumor Growth in Non-Small-Cell Lung Cancer.Krüppel-Like Factor 6 下调与非小细胞肺癌不良预后和肿瘤生长有关。
Comput Math Methods Med. 2022 Jan 30;2022:3193553. doi: 10.1155/2022/3193553. eCollection 2022.
10
MiR-630 promotes epithelial ovarian cancer proliferation and invasion via targeting KLF6.miR-630 通过靶向 KLF6 促进卵巢上皮性癌细胞的增殖和侵袭。
Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4542-4547.

引用本文的文献

1
KLF13 promotes esophageal cancer progression and regulates triacylglyceride and free fatty acid metabolism through GPIHBP1.KLF13通过GPIHBP1促进食管癌进展并调节甘油三酯和游离脂肪酸代谢。
Cell Death Dis. 2025 May 31;16(1):425. doi: 10.1038/s41419-025-07709-7.
2
Research on Correlations of lncRNA ST7-AS1 with Progression and Therapeutic Targets of Esophageal Cancer.lncRNA ST7-AS1与食管癌进展及治疗靶点的相关性研究
Turk J Gastroenterol. 2024 Dec 16;36(2):82-88. doi: 10.5152/tjg.2024.24260.
3
miR-1301-3p promotes invasion and migration and EMT progression in esophageal cancer by downregulating NBL1 expression.
miR-1301-3p 通过下调 NBL1 表达促进食管癌的侵袭和迁移及 EMT 进程。
Thorac Cancer. 2023 Oct;14(30):3032-3041. doi: 10.1111/1759-7714.15093. Epub 2023 Sep 7.
4
Hsa_circ_0001550 facilitates colorectal cancer progression through mediating microRNA-4262/nuclear casein kinase and cyclin-dependent kinase substrate 1 cascade.Hsa_circ_0001550 通过介导 microRNA-4262/核酪蛋白激酶和细胞周期蛋白依赖性激酶底物 1 级联促进结直肠癌进展。
J Clin Lab Anal. 2022 Jul;36(7):e24532. doi: 10.1002/jcla.24532. Epub 2022 Jun 13.
5
Circ_0006948 Contributes to Cell Growth, Migration, Invasion and Epithelial-Mesenchymal Transition in Esophageal Carcinoma.Circ_0006948促进食管癌的细胞生长、迁移、侵袭及上皮-间质转化。
Dig Dis Sci. 2022 Feb;67(2):492-503. doi: 10.1007/s10620-021-06894-7. Epub 2021 Feb 25.